A Study of the Helix Surgical System in Primary Open-Angle Glaucoma (POAG) and Cataract (HELIX)

Launched by SIGHT SCIENCES, INC. · Apr 21, 2025

Keywords

ClinConnect Summary

The HELIX trial is a study looking at a new surgical system called the Helix Surgical System. It aims to evaluate how safe this system is for performing cataract surgery, particularly for patients who also have mild to moderate primary open-angle glaucoma (POAG). The study will also gather early information about how well this system can help lower eye pressure, which is important for managing glaucoma.

To participate in this trial, individuals need to be at least 45 years old and have significant cataracts along with diagnosed mild to moderate POAG. They should have stable eye pressure levels and must not have had certain previous eye surgeries that could affect the results. Participants can expect to undergo cataract surgery using the Helix system and will be monitored for safety and effectiveness. This study is not yet recruiting, so potential participants will need to wait for further announcements.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male or female subjects, 45 years or older
• • Visually significant age-related cataract.
• • Intraocular pressure (IOP) at the Screening visit not exceeding 33 mmHg and at least 21 mmHg for unmedicated eyes or 16 mmHg if medicated (1 to 4 ocular hypotensive medications - fixed combinations count as the number of components), with a stable medication regimen for ≥2 months.
• • Diagnosed with mild to moderate primary open angle glaucoma (POAG).
• Exclusion Criteria:
• * Any of the following prior ocular procedures:
• • Laser trabeculoplasty ≤180 days prior to baseline
• • Durysta ≤12 months prior to baseline
• • Any implanted glaucoma device
• • Prior canaloplasty, goniotomy, trabeculotomy, trabeculectomy
• • Ciliary ablation including endoscopic cyclophotocoagulation (ECP), Cyclophotocoagulation or CPC (G probe), high intensity focused ultrasound (HIFU),
• • 180 days prior to baseline
• • Retinal laser procedure ≤3 months prior to baseline
• • Any form of glaucoma other than POAG
• • Use of topical ocular steroids.
• • Clinically significant concurrent ocular pathology or systemic medical condition which, in the Investigator's judgment, would either place the subject at increased risk of complications, contraindicate surgery, place the subject at risk of significant vision loss during the study period or interfere with compliance to elements of the study protocol
• • History of penetrating keratoplasty or another corneal transplant
• • Endothelial cell density \< 2200 cells/mm2 (age 45), \< 2000 cells/mm2 (age 46 to 55), \< 1800 cells/mm2 (age 56 to 65), \< 1600 cells/mm2 (age \> 65).
• • Retrobulbar tumor, thyroid eye disease, Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.
• • BCVA of logMAR 0.4 (20/50) or worse in the study eye not due to cataract
• • BCVA of logMAR 0.6 (20/80) or worse in the non-study eye not due to cataract.